NYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPH
Tuesday, December 06, 2022
Nymox Pharmaceutical Corporation is pleased to announce today that a new formal submission has been made by the Company in Europe for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH). The trademarked name for the product in the application is NYMOZARFEX (TM). The Marketing Authorization Application (MAA) was submitted to the Danish authorities. The Company will provide further information, including other expected submissions, when the information becomes available.
Paul Averback MD, CEO of Nymox said, "We are extremely pleased to make this announcement today. We thank our team members and many very important collaborators for their efforts and perseverance involved in the ongoing process. This product is a major innovation and there is a great need for men to have access to this technology, which is unique. We will continue to provide updates and communications whenever appropriate. The Company is very grateful for the solid support of our stakeholders."
